Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Zscaler Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $528.75 (market cap $134.25B), while Zscaler Inc trades at $176.45 (market cap $28.87B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.7× Zscaler Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.
| VRTX | ZS | |
|---|---|---|
Market Cap | $134.25B | $28.87B |
Sector | Health | Technology |
52-Week High | $529.65 | $336.27 |
52-Week Low | $376.62 | $118.05 |
Enterprise Value | $128.37B | $27.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Zscaler (ZS) trades at $176.68, up 4.74% with strong technical momentum and bullish analyst sentiment. The stock shows consistent revenue growth from $1.1B in 2022 to $2.67B in 2025, though profitability remains negative with a -2.44% net margin. Recent earnings beats and leadership in Gartner's Magic Quadrant for security platforms support positive momentum, while elevated valuation ratios (P/S 8.94, EV/EBITDA 188.83) reflect growth expectations.
Outlook remains cautiously optimistic with 79% analyst buy ratings and $191.81 consensus target, but risks include persistent unprofitability, high spending, and competitive pressures. The upcoming Q2 2026 earnings report on September 3 will be critical for validating growth trajectory amid concerns about execution and valuation sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
